Thibault Francken
Papers
1
Total Citations
14
H-Index
1
About
Thibault Francken is a virologist and drug discovery researcher whose work has centered on accelerating the development of antiviral therapies, particularly in response to the COVID-19 pandemic. His primary research areas include high-throughput screening (HTS) assay development, antiviral drug discovery, and SARS-CoV-2 virology. Francken’s most notable contribution is the development of a robust, dual-reporter HTS assay for SARS-CoV-2, which enables rapid, reliable, and fully automated screening of potential antiviral compounds. This assay, detailed in his 2022 paper (14 citations), represents a critical tool for the global scientific community, streamlining the identification of candidate drugs against emerging viral threats. By designing a convenient and scalable platform, Francken has directly addressed a key bottleneck in pandemic response: the need for efficient, high-capacity screening methods. His work exemplifies the practical, translational research essential for combating infectious diseases, and his assay has the potential to be adapted for future viral outbreaks, marking him as a contributor to the infrastructure of modern antiviral discovery.
Research Focus
Key Achievements
Top Papers
- 1